{"id":"solumatrix-abiraterone-acetate","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Adrenal insufficiency"},{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CYP17, abiraterone acetate reduces the levels of androgens, which can slow the growth of prostate cancer cells. This mechanism is particularly effective in treating castration-resistant prostate cancer.","oneSentence":"Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:22.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"},{"name":"Non-metastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT02737332","phase":"PHASE2","title":"A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-03-21","conditions":"Prostate Cancer","enrollment":53},{"nctId":"NCT02887976","phase":"PHASE3","title":"Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201","status":"COMPLETED","sponsor":"GU Research Network, LLC","startDate":"2016-09","conditions":"Prostate Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yonza","SoluMatrix™"],"phase":"phase_3","status":"active","brandName":"SoluMatrix™ Abiraterone Acetate","genericName":"SoluMatrix™ Abiraterone Acetate","companyName":"GU Research Network, LLC","companyId":"gu-research-network-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SoluMatrix Abiraterone Acetate is a small molecule inhibitor of the cytochrome P450 17A1 enzyme, specifically targeting steroid 17-alpha-hydroxylase/17,20 lyase. It is used to treat prostate cancer, as indicated by clinical trials registered on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}